Key clinical point: Initiating the tumor necrosis factor inhibitor golimumab at the same time as methotrexate significantly increased the likelihood of remission by 8 and 22 weeks in patients with early psoriatic arthritis.
Major finding: By week 22, 81% of golimumab-methotrexate patients had achieved Disease Activity Score (DAS) remission (less than 1.6) versus 42% of methotrexate-placebo patients (P = .004).
Study details: An investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial of 51 adults with CASPAR-defined psoriatic arthritis who were naive to methotrexate and biologic disease-modifying antirheumatic drugs.
Disclosures: Merck Sharp & Dohme provided medication and unrestricted funding for the study. Dr. van Mens and two coinvestigators reported having no disclosures. Several other coinvestigators disclosed ties to UCB, AbbVie, Novartis, Janssen, Eli Lilly, and other pharmaceutical companies.
van Mens LJJ et al. Ann Rheum Dis. 2019 Feb 26. doi: 10.1136/annrheumdis-2018-214746